Lifeboat Foundation

Most treatments for strokes aim to help reduce or repair damage to affected neurons. But a new study in mice has shown that a drug already in use to treat certain neurological disorders could help patients recover from strokes by getting undamaged neurons to pick up the slack.

An ischemic stroke occurs when a blood vessel blockage interrupts blood flow to the brain, causing neurons to die off. Survivors can suffer impaired fine motor control and speech, and other disabilities, for which long-term rehabilitation is often required.

Logically, many treatment options in development focus on minimizing or reversing damage to neurons, using things like stem cells, anti-inflammatory drugs, injectable hydrogels, or molecules that convert neighboring cells into neurons.

Repression of the G protein-coupled chemokine receptor CCR5 enhances MAPK/CREB signaling, long-term potentiation, somatosensory cortical plasticity, and learning and memory, while CCR5 over-activation by viral proteins may contribute to HIV-associated cognitive deficits.

Summary: Increasing synchronization of neurons in the upstream brain region that transmits information leads to a significant improvement in the transmission of information and information processing in the downstream region.

Source: Bar-Ilan University.

In the early 20th century scientists began to record brain activity using electrodes attached to the scalp. To their surprise, they saw that brain activity is characterized by slow and rapid ascending and descending signals which were subsequently called “brain waves”.

𝙏𝙝𝙚 𝙘𝙤𝙣𝙙𝙞𝙩𝙞𝙤𝙣𝙨 𝙘𝙖𝙣 𝙖𝙡𝙡 𝙖𝙛𝙛𝙚𝙘𝙩 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣, 𝙙𝙖𝙢𝙖𝙜𝙞𝙣𝙜 𝙗𝙡𝙤𝙤𝙙 𝙫𝙚𝙨𝙨𝙚𝙡𝙨 𝙖𝙣𝙙 𝙡𝙚𝙖𝙙𝙞𝙣𝙜 𝙩𝙤 𝙨𝙩𝙧𝙤𝙠𝙚𝙨. 𝘽𝙪𝙩 𝙩𝙝𝙚 𝙘𝙤𝙣𝙣𝙚𝙘𝙩𝙞𝙤𝙣 𝙗𝙚𝙩𝙬𝙚𝙚𝙣 𝙫𝙖𝙨𝙘𝙪𝙡𝙖𝙧 𝙙𝙞𝙨𝙚𝙖𝙨𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣 𝙖𝙣𝙙 𝘼𝙡𝙯𝙝𝙚𝙞𝙢𝙚𝙧’𝙨 𝙝𝙖𝙨 𝙧𝙚𝙢𝙖𝙞𝙣𝙚𝙙 𝙪𝙣𝙚𝙭𝙥𝙡𝙖𝙞𝙣𝙚𝙙 𝙙𝙚𝙨𝙥𝙞𝙩𝙚 𝙩𝙝𝙚 𝙞𝙣𝙩𝙚𝙣𝙨𝙚 𝙚𝙛𝙛𝙤𝙧𝙩𝙨 𝙤𝙛 … See more.

The Neuro-Network.

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐦𝐚𝐲 𝐡𝐚𝐯𝐞 𝐟𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐦𝐢𝐬𝐬𝐢𝐧𝐠 𝐥𝐢𝐧𝐤 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐚𝐧𝐝 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐝𝐢𝐬𝐞𝐚𝐬𝐞

Continue reading “Researchers may have found the missing link between Alzheimer’s and vascular disease” »

According to complexity economist Brian Arthur and physicist Geoffrey West human social systems function optimally as complex adaptive systems – or quantum systems.

The newly developed field of quantum leadership maps the human, conscious equivalents onto the 12 systems that define complex adaptive systems or quantum organisations. These are: self-awareness; vision and value led; spontaneity; holism; field-independence; humility; ability to reframe; asking fundamental questions; celebration of diversity; positive use of adversity; compassion; a sense of vocation (purpose).

Quantum leadership is essentially a new management approach that integrates the most effective attributes of traditional leadership with recent advances in both quantum physics and neuroscience. It is a model that allows for greater responsiveness. It draws on our innate ability to recognise, adapt and respond to uncertainty and complexity.

For the first time TU Graz’s Institute of Theoretical Computer Science and Intel Labs demonstrated experimentally that a large neural network can process sequences such as sentences while consuming four to sixteen times less energy while running on neuromorphic hardware than non-neuromorphic hardware. The new research based on Intel Labs’ Loihi neuromorphic research chip that draws on insights from neuroscience to create chips that function similar to those in the biological brain.

The research was funded by The Human Brain Project (HBP), one of the largest research projects in the world with more than 500 scientists and engineers across Europe studying the human brain. The results of the research are published in Nature Machine Intelligence (“Memory for AI Applications in Spike-based Neuromorphic Hardware”).

The close-up shows an Intel Nahuku board, each of which contains eight to 32 Intel Loihi neuromorphic research chips. (Image: Tim Herman, Intel Corporation)

Cell-Based Dairy Bio-Products For Health & Nutrition — Dr. Aletta Schnitzler, Ph.D. — CSO — Turtletree Labs

Dr. Aletta Schnitzler, PhD. is the Chief Scientific Officer at TurtleTree Labs (https://turtletree.com/) where she leads the R&D teams and spearheads an innovation roadmap to bring nutritious cell-based dairy and meat alternatives to market.

Continue reading “Dr Aletta Schnitzler — CSO — TurtleTree Labs — Cell-Based Dairy Bio-Products For Health & Nutrition” »

Summary: Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.

Source: Yale.

A recent research paper published in Nature Communications by a team led by Yale School of Medicine researchers finds a promising way to make brain cancer cells more susceptible to chemotherapy.

A mechanism that causes autism, schizophrenia, Alzheimer’s and other conditions and is shared by mutations in the genes ADNP and SHANK3 has been unraveled by Tel Aviv University researchers who developed an experimental drug they found to be effective in animal models.

The drug could also be suitable for treating a range of rare syndromes that impair brain functions, said the scientists. The researchers were led by Prof. Illana Gozes from the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine and the Sagol School of Neuroscience. The experimental drug, called Davunetide, had previously been developed in her lab.

The paper, which the team called a “scientific breakthrough,” was published in the scientific journal Molecular Psychiatry under the title “SH3-and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.”